Works matching IS 22351795 AND DT 2021 AND VI 10 AND IP 4

Results: 12

Front & Back Matter.

Published in:: Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 1, doi. 10.1159/000518567
Publication type:: Article

APPLE News.

Published in:: Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 396, doi. 10.1159/000518226
Publication type:: Article

Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?

Published in:

2021

By:

Kudo, Masatoshi

Publication type:

Editorial

Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.

Published in:

Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 380, doi. 10.1159/000516899

By:

Morita, Masahiro;
Nishida, Naoshi;
Sakai, Kazuko;
Aoki, Tomoko;
Chishina, Hirokazu;
Takita, Masahiro;
Ida, Hiroshi;
Hagiwara, Satoru;
Minami, Yasunori;
Ueshima, Kazuomi;
Nishio, Kazuto;
Kobayashi, Yukari;
Kakimi, Kazuhiro;
Kudo, Masatoshi

Publication type:

Article

Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?

Published in:

2021

By:

Ravaioli, Matteo;
Piscaglia, Fabio;
Cillo, Umberto;
Brandi, Giovanni;
Sessa, Maurizio;
Germinario, Giuliana;
Golfieri, Rita;
Cappelli, Alberta;
Morelli, Maria C.;
Siniscalchi, Antonio;
D'Errico, Antonietta;
Cescon, Matteo;
Iannone, Primiano;
Trevisani, Franco

Publication type:

Letter

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma.

Published in:

Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 370, doi. 10.1159/000515551

By:

Tovoli, Francesco;
Dadduzio, Vincenzo;
De Lorenzo, Stefania;
Rimassa, Lorenza;
Masi, Gianluca;
Iavarone, Massimo;
Marra, Fabio;
Garajova, Ingrid;
Brizzi, Maria Pia;
Daniele, Bruno;
Trevisani, Franco;
Messina, Carlo;
Di Clemente, Francesco;
Pini, Sara;
Cabibbo, Giuseppe;
Granito, Alessandro;
Rizzato, Mario Domenico;
Zagonel, Vittorina;
Brandi, Giovanni;
Pressiani, Tiziana

Publication type:

Article

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.

Published in:

Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 360, doi. 10.1159/000515490

By:

Finkelmeier, Fabian;
Scheiner, Bernhard;
Leyh, Catherine;
Best, Jan;
Fründt, Thorben Wilhelm;
Czauderna, Carolin;
Beutel, Alica;
Bettinger, Dominik;
Weiß, Johannes;
Meischl, Tobias;
Kütting, Fabian;
Waldschmidt, Dirk-Thomas;
Radu, Pompilia;
Schultheiß, Michael;
Peiffer, Kai-Henrik;
Ettrich, Thomas J.;
Weinmann, Arndt;
Wege, Henning;
Venerito, Marino;
Dufour, Jean-Francois

Publication type:

Article

Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.

Published in:

Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 346, doi. 10.1159/000515305

By:

Hsu, Chia-Lang;
Ou, Da-Liang;
Bai, Li-Yuan;
Chen, Chia-Wei;
Lin, Li;
Huang, Shiu-Feng;
Cheng, Ann-Lii;
Jeng, Yung-Ming;
Hsu, Chiun

Publication type:

Article

Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis.

Published in:

Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 330, doi. 10.1159/000515304

By:

Huang, Junjie;
Lok, Veeleah;
Ngai, Chun Ho;
Chu, Cedric;
Patel, Harsh K.;
Thoguluva Chandraseka, Viveksandeep;
Zhang, Lin;
Chen, Ping;
Wang, Shanjuan;
Lao, Xiang-Qian;
Tse, Lap Ah;
Xu, Wanghong;
Zheng, Zhi-Jie;
Wong, Martin C.S.

Publication type:

Article

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.

Published in:

Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 320, doi. 10.1159/000514313

By:

Zhu, Xiao-Dong;
Huang, Cheng;
Shen, Ying-Hao;
Ji, Yuan;
Ge, Ning-Ling;
Qu, Xu-Dong;
Chen, Lingli;
Shi, Wen-Kai;
Li, Mei-Ling;
Zhu, Jin-Jin;
Tan, Chang-Jun;
Tang, Zhao-You;
Zhou, Jian;
Fan, Jia;
Sun, Hui-Chuan

Publication type:

Article

Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals.

Published in:

Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 309, doi. 10.1159/000513705

By:

Minami, Tatsuya;
Tateishi, Ryosuke;
Fujiwara, Naoto;
Nakagomi, Ryo;
Nakatsuka, Takuma;
Sato, Masaya;
Uchino, Koji;
Enooku, Kenichiro;
Nakagawa, Hayato;
Fujinaga, Hidetaka;
Izumiya, Masashi;
Hanajiri, Kazuyuki;
Asaoka, Yoshinari;
Kondo, Yuji;
Tanaka, Yasuo;
Otsuka, Motoyuki;
Ohki, Takamasa;
Arai, Masahiro;
Tanaka, Atsushi;
Yasuda, Kiyomi

Publication type:

Article

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.

Published in:

Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 296, doi. 10.1159/000513486

By:

Qin, Shukui;
Ren, Zhenggang;
Feng, Yin-Hsun;
Yau, Thomas;
Wang, Baocheng;
Zhao, Haitao;
Bai, Yuxian;
Gu, Shanzhi;
Li, Lindong;
Hernandez, Sairy;
Xu, Derek-Zhen;
Mulla, Sohail;
Wang, Yifan;
Shao, Hui;
Cheng, Ann Lii

Publication type:

Article